PMID 40240614

Research
All papers

Exercise and cancer-related lymphedema in the lower limbs-a randomized cross-over trial on high-intensity interval training (HIIT) with and without compression garments

Question

Is supervised stationary-bike HIIT acceptable and safe for people with cancer-related lower limb lymphedema, and do immediate responses differ when performed with versus without compression garments?

Summary

This randomized crossover trial tested two supervised stationary-bike HIIT sessions in adults with cancer-related lower limb lymphedema: one with compression garments and one without. Completion and acceptability were high, no adverse events were reported, and symptom and limb-volume changes did not differ meaningfully between compression conditions, although small objective changes in soft tissue mass and extracellular fluid favored compression.

Methodology

  • Twenty-one adults with cancer-related lower limb lymphedema using daily made-to-measure compression garments.
  • 21 participants.
  • Stationary cycling.
  • Work intervals: Seven 1-minute intervals at the final power output reached during GCT-TT.
  • Recovery: 1-minute recoveries at approximately 50% of final GCT-TT power, Borg 10-11.
  • Intensity: Individualized prescribed power; final GCT-TT intensity approximately Borg 15-16 or 60-84% VO2max.
  • 23 minutes.
  • One acute session in this condition.
  • Acute crossover session.
  • Randomized crossover trial with two acute HIIT sessions separated by a 7-day washout.
  • Acceptability, Adverse events, Pain, heaviness, and tension, and Affected-limb volume were tracked.

Outcomes

Completion

Twenty-one of 35 eligible patients were included and 19 of 21 allocated participants completed both sessions.

Recruitment/allocation 60%; completion 90%.

Improved

Acceptability

Most participants were satisfied or very satisfied after both conditions.

No compression: 18/20 very satisfied. Compression: 15/19 very satisfied and 3/19 satisfied.

Improved

Adverse events

No adverse events or serious adverse events were reported. Two participants reported DOMS after the first session but completed both sessions.

Serious adverse events: 0/20 no compression and 0/19 compression.

No clear change

Symptoms and limb volume

There were no between-condition differences in pain, heaviness, tension, or affected-limb volume change.

Volume between-session difference -18.7 ml (95% CI -150.2 to 112.8), p=0.8; symptom CIs crossed no difference.

No clear change

Soft tissue mass and extracellular fluid

Soft tissue mass and L-Dex differences favored compression, but authors interpreted the differences as small and not clinically important.

Soft tissue mass difference -164.2 g (95% CI -298.2 to -30.2), p=0.02; L-Dex difference -4.8 (95% CI -9.1 to -0.5), p=0.03.

Mixed

Insights

  • For selected adults with lower limb lymphedema, supervised cycling HIIT can be feasible acutely when intensity is individualized.
  • Compression during exercise may not be necessary for every short supervised session, but decisions should be individualized and clinical.
  • Some compression configurations can reduce comfort or perceived movement freedom during exercise.
  • This is safety/feasibility evidence, not evidence for long-term fitness or lymphedema improvement.

Limitations

  • Only two acute HIIT sessions were tested.
  • No long-term follow-up for lymphedema symptoms or objective outcomes.
  • No participant blinding and assessor blinding was not feasible.
  • Selection bias risk because HIIT may appeal to fitter participants and recruitment included social media.
  • Participants were relatively young with low BMI and low affected-limb volume compared with other LLL exercise trials.
  • Sub-garment pressure was not measured.
  • No objective reassessment at 3-4 hours or 24 hours.

Safety

  • No adverse events were reported.
  • No serious adverse events occurred in either condition.
  • Two participants reported delayed onset muscle soreness after the first session and completed both sessions.
  • Three participants needed target power reductions of 10, 20, and 25 W.